Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Cannabidiol Oral Solution in pediatric treatment-resistant seizures
NCT02318602Phase 3Completed
- Sponsor
- Insys Therapeutics
- Start
- Jan 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cannabidiol in seizure disorder, Lennox-Gastaut syndrome (LGS), Dravet syndrome, sponsored by Insys Therapeutics. Started Jan 2016; status: completed.
02
Drugs
cannabidiol
03
Conditions
seizure disorderLennox-Gastaut syndrome (LGS)Dravet syndrome
Beyond the preview
Go deeper on NCT02318602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318602.